- Home
- SNDX vs TFIN Comparison
SNDX vs TFIN Comparison
Compare SNDX & TFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- TFIN
- Stock Information
- Founded
- SNDX 2005
- TFIN 1981
- Country
- SNDX United States
- TFIN United States
- Employees
- SNDX N/A
- TFIN N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- TFIN Major Banks
- Sector
- SNDX Health Care
- TFIN Finance
- Exchange
- SNDX Nasdaq
- TFIN Nasdaq
- Market Cap
- SNDX 1.1B
- TFIN 1.3B
- IPO Year
- SNDX 2016
- TFIN N/A
- Fundamental
- Price
- SNDX $10.70
- TFIN $57.44
- Analyst Decision
- SNDX Strong Buy
- TFIN Hold
- Analyst Count
- SNDX 11
- TFIN 6
- Target Price
- SNDX $35.91
- TFIN $68.50
- AVG Volume (30 Days)
- SNDX 2.3M
- TFIN 285.6K
- Earning Date
- SNDX 05-05-2025
- TFIN 04-16-2025
- Dividend Yield
- SNDX N/A
- TFIN N/A
- EPS Growth
- SNDX N/A
- TFIN N/A
- EPS
- SNDX N/A
- TFIN 0.37
- Revenue
- SNDX $43,722,000.00
- TFIN $401,390,000.00
- Revenue This Year
- SNDX $263.44
- TFIN $12.09
- Revenue Next Year
- SNDX $129.44
- TFIN $14.37
- P/E Ratio
- SNDX N/A
- TFIN $154.13
- Revenue Growth
- SNDX N/A
- TFIN 0.68
- 52 Week Low
- SNDX $9.66
- TFIN $42.90
- 52 Week High
- SNDX $25.07
- TFIN $110.58
- Technical
- Relative Strength Index (RSI)
- SNDX 38.98
- TFIN 59.39
- Support Level
- SNDX $9.67
- TFIN $52.59
- Resistance Level
- SNDX $14.24
- TFIN $55.93
- Average True Range (ATR)
- SNDX 0.93
- TFIN 2.10
- MACD
- SNDX -0.26
- TFIN 1.05
- Stochastic Oscillator
- SNDX 22.62
- TFIN 93.45
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About TFIN Triumph Financial Inc.
Triumph Financial Inc is a financial holding company. The company has four reportable segments namely Banking, Factoring, Payments, and Intelligence. The Banking segment includes the operations of TBK Bank. The Factoring segment includes the operations of Triumph Financial Services with revenue derived from factoring services, The Payments segment includes the operations of TBK Bank's TriumphPay division which provides a presentment, audit and payment solution to Shipper, Broker, and Factor clients in the trucking industry and The Intelligence segment includes to turn the over-the-road trucking data collected through the services into actionable insights for their customers.